Patents.

The decision by India's patent office bars other companies from making cheaper copies of the vaccine and allows Pfizer to exclusively sell it in India until 2026. It's a big victory for the U.S. drugmaker in a market that has the world's largest number of pneumonia cases, a lung disease that kills nearly a million children a year globally.